2 February 2023
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Gene Therapy
Logistics
In this Tech Demo, James Kusena, Vice President of Bioprocessing and Applications at MicrofluidX, tells us about their core technology, The Cyto Engine, as seen at Advanced Therapies Week 2023.
The Cyto Engine addresses the difficulties of translating, manufacturing and commercialising cell therapies in a cost effective manner.
James explains how this technology has demonstrated to offer superior process efficiency, repeatability and cell health.
This demo has been produced in partnership with MicrofluidX.
 |
 |
More like this
Gilead’s Yescarta Demonstrates Improvement in Overall Survival for Aggressive Blood Cancers
Kite’s Yescarta CAR-T cell therapy has demonstrated significant improvement for the treatment of relapsed/refractory large B-cell lymphoma from its Phase III ZUMA trial.
23 March 2023
Pfizer Invests $43 Billion to Acquire Seagen
Pfizer is to acquire global technology company Seagan in a definitive merger agreement for a total enterprise value of $43 billion.
14 March 2023
Early Adoption and Partnerships – The Secret to Commercialization Success?
This Briefing from Advanced Therapies Week 2023 focusses on how partnerships within the industry can advance research from the clinic to manufacturing scale, to keep pace with the evolving field.
2 March 2023
Discover more like this
